Rechallenge with PD-1/PD-L1 inhibitors after a (un)planned interruption may offer a potential safety net for patients with disease progression. At ESMO Congress 2019, results from a study systematically investigating this approach for the first time…
Read More
As genetic analysis becomes cheaper and more widely available, oncologists are getting close to an era where tumour—somatic—and germline testing will form a greater component of the management of adolescents and young adults (AYA) with…
Read More
Offering the trastuzumab–chemotherapy combination to all those with HER2-positive early-stage breast cancer has benefitted many but has led to the overtreatment of an increasing proportion of patients. Adding unnecessary treatments to an effective regimen increases…
Read More
The topic was debated on Saturday in a session as part of the Young Oncologist Track, highlighting the pros and cons of the two different approaches currently in use. There is no question that the clinical benefit and safety…
Read More
Ras oncogene means different things to different tumours in different tissues. Step away from RAS itself and we enter a universe of complex and diverse biological processes that Ras oncogene orchestrates. In my view, deep…
Read More
